MediciNova, Inc. (NASDAQ:MNOV) Agree With Japan’s Mie University and Biocomo to Develop a Vaccine for the Novel Coronavirus Jointly

The pharmaceutical industry is convinced that there is still room to combat the rapid spread of coronavirus. It has emphasized the need for companies to work together to tap into each other’s expertise in the development of potential vaccines. This is what MediciNova, Inc. (NASDAQ:MNOV) has done.

The company has entered into a joint development deal with BioComo and Mie University, whereby the latter two have granted MediciNova exclusive rights to use BC-PIV, a human parainfluenza virus type 2 vector. BC-PIV is co-developed by BioComo and Mie University, and it believed that it will enhance the development of a novel vaccine.

The Approach behind the Development of a Novel BC-PIV SARS-Cov-2 Vaccine

The CEO of MediciNova, Inc. Yuichi Iwaki, says, they have a mission and are willing to initiate a project which can put the SARS-CoV-2, the very serious and potentially fatal disease under control. Hence they are enthusiastic about the collaboration with BioComo and Mie University.

“Given the current global pandemic of COVID-19, we appreciate this very important opportunity to jointly develop a vaccine against SARS-CoV-2 with BC-PIV…’’ Iwaki explained. Besides, the possibility of developing a BC-PIV SARS-CoV-2 vaccine as an intra-nasal formulation and as an intramuscular injection is such a noble idea.

The former is expected to induce local mucosal immunity. The latter is said to have a high affinity to nasal and upper respiratory tract mucosa, which is relatively the same route followed by SARS-CoV-2 natural infection.

This is not the first time that MediciNova is taking on such a significant task. The company has been at the helm of trying to meet the unmet medical needs and has established a proven track record.

Biocomo’s Dedication to Invent New and Promising Vaccine

The company has successfully used BC-PIV to develop vaccines against Ebola and RS viruses. This only explains how confident they are with this technology in the development of SARS-CoV-2 vaccines. Its mission is to raise the technology to a level where they can invent new and promising products. The invention will enhance the quick and economical production of those vaccines as well as future collaborations.